<DOC>
	<DOCNO>NCT02179749</DOCNO>
	<brief_summary>This 8-week , randomize , double-blind , placebo-controlled , 3 arm , parallel group , dose-ranging study 1-week treatment mifepristone ( 0 , 600 , 1200 mg/d ) give conjunction 8 week manual-guided counseling , follow-up visit Week 12 .</brief_summary>
	<brief_title>Mifepristone Treatment Alcohol Use Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Alcohol Drinking</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<criteria>Male female volunteer , 1865 year age Meets Diagnostic Statistical Manual ( DSM ) V criterion current alcohol use disorder moderate great severity , define DSMV â‰¥ 4 symptom Abstinent minimum 3 day ( 30 day ) prior randomization In acceptable health judgment study physician , basis interview , medical history , physical exam , ECG , urine test lab test Females childbearing potential must negative serum pregnancy test screen visit negative urine pregnancy test randomization agree use nonhormonal effective birth control study duration one month thereafter A medical condition chronic use medication contraindicate administration mifepristone Significant medical disorder clinically significant finding ECG ( e.g. , prolongation correct QT interval , urine blood test increase potential risk interfere study participation determine Study Physician . Note : serum potassium normal range must replace normal prior randomization ; individual serum potassium outside range normal randomize Liver function test 3 time upper limit normal elevate bilirubin Female subject childbearing potential pregnant , nursing , refuse use effective non hormonal birth control 1week medication administration one month thereafter Meets Diagnostic Statistical Manual V criterion major Axis I disorder include mood anxiety disorder substance use disorder alcohol nicotine use disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Alcohol-Related Disorders</keyword>
	<keyword>Substance-Related Disorders</keyword>
	<keyword>Mental Disorders</keyword>
	<keyword>Mifepristone</keyword>
	<keyword>Glucocorticoid Antagonists</keyword>
	<keyword>Alcohol Treatment</keyword>
	<keyword>Alcohol</keyword>
</DOC>